Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

A new COVID-19 variant is spreading rapidly through the U.S. What to know about NB.1.8.1 and its symptoms in Tennessee.

NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...

Immunology is the branch of biomedical sciences concerned with all aspects of the immune system in all multicellular organisms. CD8 + T cell exhaustion and dysfunction are features of a number of ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company.

A new COVID-19 strain has been reported in dozens of countries, including the U.S. Here's what you should know about it.

Dr Robert Köchl from King's College London is co-leading a research project that has been awarded a £1.4 million Programme Foundation Award from ...

Immunewalk Therapeutics Announces Positive Topline Phase 1 SAD Data For Immunology And Inflammation Drug Candidate IW-601. Date. 2025-06-11 08:16:03. Share on Facebook; Tweet on Twitter ...